Think of Evinacumab as Another Niche Med for Lowering LDL
January 2024
Evinacumab (Evkeeza) will be a new monoclonal antibody to lower LDL in kids and adults with homozygous familial hypercholesterolemia.
This rare condition is the most severe form of familial hypercholesterolemia...occurring in about 1 in 300,000 Canadians, with a slightly higher incidence in French Canadians.
These patients are at greater risk for early CV events or cardiac death from dangerously high LDL...with levels often over 10 mmol/L.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive